I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Akero Therapeutics' share price is tanking after biotech's NASH drug fails to meet its primary endpoint in a Phase 2B study. Find out why AKRO stock is a Buy.

What happenedShares of Akero Therapeutics (NASDAQ: AKRO) were down more than 70% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Akero Therapeutics Inc (NASDAQ: AKRO) says its candidate treatment for a serious liver disease demonstrated exceptional safety and efficacy in a Phase 2b study. A 50-milligram dose of efruxifermin ...

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

In the last 3 months, 6 analysts have offered 12-month price targets for Akero Therapeutics. The company has an average price target of $62.67 with a high of $83.00 and a low of $33.00.

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH.

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic ...

Akero's 50mg EFX led to a 24% effect size for cirrhosis reversal over placebo in week 96 biopsies, highlighting treatment potential. Non-GLP-1 subgroup saw 45% cirrhosis reversal with EFX, showing ...